MYC is one of the most commonly activated oncogenes mediating cancer initiation and progression, and it regulates the expression of two immune checkpoints, CD47 and PD-L1, by directly binding to their promoters, leading to the identification of MYC as a target for immunotherapy resistance [281]. The gene discussed is CD274; the disease is cancer.